Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Lancet Oncol 2023 Mar 01;24(3)273-285, SM Tolaney, P Tarantino, N Graham, N Tayob, L Parè, G Villacampa, CT Dang, DA Yardley, B Moy, PK Marcom, KS Albain, HS Rugo, MJ Ellis, I Shapira, AC Wolff, LA Carey, R Barroso-Sousa, P Villagrasa, M DeMeo, M DiLullo, JGT Zanudo, J Weiss, N Wagle, AH Partridge, AG Waks, CA Hudis, IE Krop, HJ Burstein, A Prat, EP WinerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.